Form D · Pharmaceuticals
Ribometrix, Inc.
Greenville, NC · CIK 0001718794
Offering snapshot reported Nov 19, 2018 · SEC filing
- Reported sold
- $15M Offering amount: $30M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 5, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 19, 2018 | Initial | $14,999,998 | No comparison | 16 | SEC filing |
| Oct 11, 2017 | Initial | $3,500,000 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-326066
Source: Form D, filed Nov 19, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Dial | Director |
| Mike Dial | Director |
| Hakan Goker | Director |
| John Gustofson | Director |
| William Marshall | Director |
| Joshua Resnick | Director |
| Michael Ross | Director |
| Michael Solomon | Director, Executive |
| Katherine Warner | Executive |
| Kevin Weeks | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1800 North Greene St., Suite E
Greenville, NC, 27834
Greenville, NC, 27834